Altasciences

Our industry moves fast. And while having a clear vision and direction is important, so is giving teams the space and infrastructure to be curious and question the status quo. We do this by listening to our teams, communicating transparently, and staying flexible when things change. #DrugDevelopment #LifeScience #WhatMotivatesMe Robert Sabelli

Looking for a CRO that’s as committed to your success as you are?  At Altasciences, scientific integrity and flexibility are at the core of everything we do. We offer a wide range of non-GLP and GLP 𝘪𝘯 𝘷𝘪𝘷𝘰 safety assessments in both rodent and non-rodent species—backed by expert scientific and regulatory guidance to support your IND/NDA-enabling studies. Let’s move your program forward, together. Contact us today: https://lnkd.in/duwEkmTQ #DrugDevelopment #PreclinicalResearch #CRO

𝟮𝟬𝟭𝟲 → 𝟮𝟬𝟮𝟲: 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗴𝗿𝗼𝘄𝘁𝗵, 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗼𝘂𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀. What began as a clinical and bioanalytical CRO is now an end-to-end drug development organization supporting sponsors from lead candidate selection to early clinical proof-of-concept—and beyond. And it’s all thanks to our clients and employees who have helped us turn our vision of a reimagined drug development journey into a reality.  Where will the next decade take us? #WeAreAltasciences #DrugDevelopment #CRO

The recent adoption of ICH Q14 and the revised Q2(R2) guidelines represent a significant evolution in how analytical procedures used across preclinical, clinical, and manufacturing programs are developed, validated, and maintained, emphasizing risk-based design, robustness, and lifecycle performance. In this edition of the Consultant’s Corner, pharmaceutical scientist Ken Phares, pharmaceutical scientist and industry consultant, takes to the blog to break down what’s new, how the guidelines work together, and when to use univariate or multivariate strategies in real-world analytical development. Continue reading: https://lnkd.in/ePznj-5Y #DrugDevelopment #LifeSciences #RegulatoryAffairs

Over the past 30 years, contract research organizations have transformed from overflow vendors to strategic partners driving innovation in drug development. In this blog we look back at the evolution of the industry, from early outsourcing trends to the potential of today’s AI-enhanced research landscape. Science, technology, and talent shifts have reshaped the way new therapies are discovered, tested, and delivered, and we’re still making progress every day. Read more: https://lnkd.in/eE8YsWXR #DrugDevelopment #ContractResearchOrganization #WeAreAltasciences

Every new job starts with a conversation, and for many at our Canadian sites, that first conversation was with Julie Gagnon. As Senior Talent Acquisition Advisor, Julie’s role involves partnering with hiring managers, getting to know future Altascientists, and helping people make their next career move. Here’s what a day in the world of talent acquisition looks like. #WeAreAltasciences #DrugDevelopment #Hiring

We provide comprehensive preclinical and bioanalytical solutions to support your gene therapy program. With 175+ studies completed, our expert team ensures efficient and effective pharmacology, toxicology, and bioanalytical study conduct. Speak with one of our experts today: https://lnkd.in/duwEkmTQ #DrugDevelopment #PreclinicalResearch #CRO

Our cGMP manufacturing and analytical testing facility has been moving molecules from benchtop to market for decades. Dosage forms we manufacture and package for your preclinical and clinical studies, as well as your commercial batches, include tablets, liquid- and powder-filled hard-shell capsules, over-encapsulated capsules, spray-dried dispersions, injectables, liquids and suspensions, creams, and gels. Contact us to discuss your specific drug development needs. https://lnkd.in/eZMnPVF #PharmaceuticalManufacturing #DrugDevelopment #CDMO

Too many ophthalmic programs lose time and resources for reasons that are entirely preventable. That’s why we’ve created a short educational video, drawing on decades of experience, to highlight the key factors that truly drive success in ophthalmic preclinical studies. Catch our quick video to learn: • Key trends driving demand for new ophthalmic therapies • Our specialized preclinical ocular expertise • Smart study design choices (species, routes, drug modalities) • The procedures that make or break ocular studies Watch the video: https://lnkd.in/eggZhM44 #DrugDevelopment #Preclinical #OcularResearch

Catherine Konidas, Chief Administrative Officer, was named one of Enterprise Wired’s Top Visionary Business Leader to Watch in 2026. Read the article to discover how Cathy’s philosophy of empowerment, transparency, open dialogue, and growth opportunities for employees is cultivating talent and inspiring out-of-the-box solutions. https://lnkd.in/dRWc-wet #WeAreAltasciences #DrugDevelopment #EnterpriseWired